StockData
Trulieve Cannabis Corp. logo

Trulieve Cannabis Corp. (TRLV) stock

TRLVNYSEMedicinal Chemicals & Botanical ProductsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 5/3022% below fair value
$10.02−0.05 (-0.50%)

Close on Nov 18, 2026Market cap $1.93BP/E –Yield –

Earnings

Trulieve Cannabis's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Feb 25, 2027
Q4 FY2026 · estimated, before the open
Revenue, Q3 FY2026
$230.00M
-20.1% on a year earlier
Adjusted Diluted EPS, Q3 FY2026
$0.09
-$0.07 a year earlier
Latest guidance
Issued
Feb 29, 2024 · 1 item

Quarterly results

Revenue and earnings per share from each of Trulieve Cannabis's earnings releases, newest first

QuarterReportedRevenueYoYEPSAdj. EPSSource
Q4 FY2026ended Dec 31, 2026Feb 25, 2027Expected–––––
Q3 FY2026ended Sep 30, 2026Nov 5, 2026before the open$230.00M-20.1%$0.00$0.09Release
Q1 FY2026ended Mar 31, 2026May 7, 2026before the open$287.00M-3.7%$0.02$0.10Release
Q4 FY2025ended Dec 31, 2025Feb 26, 2026before the open$293.00M-2.7%-$0.23-$0.02Release
Q3 FY2025ended Sep 30, 2025Nov 5, 2025before the open$288.00M+1.4%-$0.14-$0.07Release
Q2 FY2025ended Jun 30, 2025Aug 6, 2025before the open$302.00M-0.3%––Release
Q1 FY2025ended Mar 31, 2025May 7, 2025before the open$298.00M0.0%––Release
Q4 FY2024ended Dec 31, 2024Feb 27, 2025before the open$301.00M+4.9%-$0.26$0.02Release
Q3 FY2024ended Sep 30, 2024Nov 5, 2024before the open$284.00M+3.3%-$0.32-$0.06Release
Q2 FY2024ended Jun 30, 2024Aug 6, 2024before the open$303.00M+7.4%-$0.04$0.00Release
Q1 FY2024ended Mar 31, 2024May 9, 2024before the open$298.00M+3.1%-$0.16-$0.05Release
Q4 FY2023ended Dec 31, 2023Feb 29, 2024before the open$287.00M-5.0%-$0.18-$0.12Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

No open guidance: every period Trulieve Cannabis guided for has been reported

Guidance history

Every forecast Trulieve Cannabis put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Feb 29, 2024cash flow from operationsFY2024$225.00MNew
Nov 9, 2023free cash flow generationFY2023$70.00MNew
Nov 9, 2023cash flow from operationsFY2023$100.00MNew
Nov 9, 2022Adjusted EBITDAFY2022$415.00M – $450.00MReaffirmed
Nov 9, 2022revenueFY2022$1.25B – $1.30BReaffirmed
Aug 10, 2022Adjusted EBITDAFY2022$415.00M – $450.00MLowered
Aug 10, 2022revenueFY2022$1.25B – $1.30BLowered
May 12, 2022adjusted EBITDA*FY2022$450.00M – $500.00MReaffirmed
May 12, 2022expected revenueFY2022$1.30B – $1.40BNew
Mar 30, 2022adjusted EBITDA*FY2022$450.00M – $500.00MNew
Mar 30, 2022expected revenueFY2022$1.30B – $1.40BNew

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Trulieve Cannabis filed with the SEC as exhibits to Form 8-K or 6-K

  1. Results
  2. Results
  3. Update
  4. Update
  5. News
  6. Results
  7. Results
  8. Results
  9. Results
  10. News
  11. News
  12. News
  13. Results
  14. Results
  15. News

See a number that looks wrong?